The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

APLS FINANCIAL STATEMENTS

Apellis Pharmaceuticals Inc — balance sheet, income statement and cash flow trends

APLSApellis Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
01 B202120222023202420252026

Profit Funnel

Q1 2026 · TTM
Revenue1.1 B $Gross Profit996.1 M $ · 90%Operating Income165.2 M $ · 15%Pre-tax Income135.1 M $ · 12%Net Income to Owners133.3 M $ · 12%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue1.1 B $+42.5%
Gross Profit996.1 M $+54.8%
Operating Income165.2 M $—
EBITDA180.1 M $—
Net Income to Owners133.3 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0500 M1 B202120222023202420252026

Capital Structure

Q1 2026
Total Assets1.1 B
  • Equity414.9 M $38%
  • Current Liabilities283.4 M $26%
  • Long-term Liabilities384.2 M $35%

Key Figures

YoY change
Total Assets1.1 B $+34.1%
Total Liabilities667.6 M $+3.8%
Total Equity414.9 M $+152.7%
Cash & ST Investments406.7 M $+13.5%
Total Debt475.8 M $+1.3%
Net Debt69 M $-37.9%

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-600 M-400 M-200 M0202120222023202420252026

Cash Flow Bridge

Q1 2026 · TTM
020 M40 M37.8 M $Operating-305 K $Investing8.7 M $Financing46.1 M $Net Change

Key Figures

YoY change
Operating Cash Flow37.8 M $—
Capital Expenditures402 K $+240.7%
Free Cash Flow37.8 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on APLS

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 1, 26. This content is for informational purposes only and is not investment advice.